Telix Pharmaceuticals is trading at A$15.69, up 4.01%, with broader biotech strength the likeliest explanation; no clear company-specific announcement explains the move.
- On October 14, Telix announced 20 abstracts for the October 17–21 EANM congress, including updates on pivotal cancer trials.
- The supplied sector context reports XBI up 2.20% and Australian biotech/pharma also higher.